Group 1 - The core viewpoint of the articles highlights the performance and valuation of Canan Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of July 24, the stock price of Canan Technology closed at 23.27 yuan, reflecting a 3.51% increase, with a rolling PE ratio of 79.62, marking a new low in 84 days, and a total market value of 2.845 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning Canan Technology at the 100th rank within the industry [1][2] Group 2 - In terms of capital flow, on July 24, Canan Technology experienced a net inflow of 10.8779 million yuan, with a total inflow of 1.5107 million yuan over the past five days [1] - The company specializes in the research, production, and sales of injection puncture instruments and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for the first quarter of 2025 show that Canan Technology achieved an operating income of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

证券代码：301122 证券简称：采纳股份 公告编号：2025-067 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意采纳科技股份有限公司首次公开发 行股票注册的批复》（证监许可[2021]3937 号），公司获准向社会公开发行人民 币普通股（A 股）股票 2,350.88 万股，每股面值人民币 1 元，发行价格为人民 币 50.31 元/股，募集资金总额为人民币 1,182,727,728.00 元，扣除各项发行费 用人民币 85,465,325.60 元（不含税），实际募集资金净额为人民币 1,097,262,402.40 元。 上述募集资金已于 2022 年 1 月 21 日划至公司指定账户。中汇会计师事务所 （特殊普通合伙）对公司首次公开发行股票募集资金到位情况进行了审验，并出 具了"中汇会验[2022]0084 号"的验资报告。 二、募集资金专户开立情况 为规范公司募集资金管理和使用，保护投资者权益，根据《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》、《深圳证券交易 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canar Medical Co., which has a current PE ratio of 77.63, marking a new low in 78 days, with a total market capitalization of 2.774 billion yuan [1][2] - Canar Medical's main business includes the research, production, and sales of injection and puncture instruments and laboratory consumables, and it has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest quarterly report for Q1 2025 shows that Canar Medical achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34% year-on-year, with a gross profit margin of 31.15% [1] Group 2 - In terms of industry comparison, the average PE ratio for the medical device industry is 52.71, with a median of 37.14, positioning Canar Medical at the 98th rank within the industry [1][2] - The number of shareholders for Canar Medical has increased to 7,596, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canan Technology Co., Ltd., particularly its high PE ratio compared to industry averages [1][2] - As of July 16, Canan's closing price was 22.24 yuan, with a rolling PE ratio of 76.09 times, significantly higher than the industry average of 51.87 times and the median of 37.48 times [1][2] - The company has a total market capitalization of 2.719 billion yuan, ranking 99th in the medical device industry based on PE ratio [1][2] Group 2 - In terms of capital flow, Canan experienced a net outflow of 1.283 million yuan on July 16, with a total outflow of 3.9893 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of injection and puncture instruments and laboratory consumables, and it has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for Q1 2025 show that Canan achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

Group 1 - The board of directors of Canar Technology Co., Ltd. held its 15th meeting of the third session on July 14, 2025, where all eight attending directors unanimously agreed to waive the advance notice requirement for the meeting [1][2] - The meeting was convened to address the resignation of Mr. Hou Peng, which resulted in the board having fewer members than stipulated in the company's articles of association. Ms. Ji Chunxia was nominated as a candidate for a non-independent director to ensure compliance with legal and regulatory requirements [1][2] - The board's resolution to nominate Ms. Ji Chunxia requires approval from the shareholders' meeting, which is scheduled to be held on July 31, 2025 [2]

Meeting Announcement - The company will hold its third extraordinary general meeting of shareholders on July 31, 2025, at 14:30 [1] - The meeting will be conducted in accordance with relevant laws and regulations, including the Company Law and the Securities Law of the People's Republic of China [1] Voting Procedures - Shareholders can participate in the meeting either in person or through authorized representatives [2] - Online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system on the same day [2][7] - Shareholders must choose either in-person voting or online voting, and duplicate votes will be disregarded, with the first valid vote counted [2] Registration Details - Registration for the meeting is required for both corporate and individual shareholders, with specific documentation needed [3][4] - Shareholders can also register via mail, email, or fax if they are unable to attend in person [4] Agenda Items - The meeting will review proposals, including the election of a non-independent director for the third board of directors [2][5] - Detailed information about the proposals will be disclosed on the company's official information platform [2] Contact Information - For inquiries, shareholders can contact the company via phone or email, with specific contact persons listed [4][6]

Core Viewpoint - The company announced the resignation of non-independent director Mr. Hou Peng and the election of Ms. Ji Chunxia as a new non-independent director, pending approval at the shareholders' meeting [1]. Group 1: Board Changes - Mr. Hou Peng has resigned from his position as a non-independent director [1]. - The third meeting of the third board of directors was held on July 14, 2025, where the proposal to elect Ms. Ji Chunxia as a non-independent director was approved [1]. Group 2: New Director Profile - Ms. Ji Chunxia, born in 1980, holds a college degree in business management and has been with the company in various roles since 2007 [4]. - She has served as the office director of Jiangyin Canar Technology Co., Ltd. from 2007 to February 2017 and as the office director of Jiangsu Canar Medical Technology Co., Ltd. since February 2017 [4]. - As of the announcement date, Ms. Ji Chunxia indirectly holds 156,000 shares of the company through Wuxi Weida Feng Investment Enterprise (Limited Partnership) [4].

Group 1 - The resignation of non-independent director Zhao Lijie was due to internal work adjustments, and he will continue to hold other positions within the company [1] - Zhao Lijie's resignation will not reduce the board's number below the legal minimum, and his resignation is effective upon delivery of the written notice [1] - Zhao Lijie has not directly held any shares in the company and has no unfulfilled commitments [1] Group 2 - Zhao Lijie was recognized for his diligent service and contributions to the company during his tenure as a non-independent director [2] - The company held its first employee representative meeting on July 14, 2025, where Zhao Lijie was elected as the employee representative director for the third board, with a term until the board's term ends [2] - Zhao Lijie meets the qualifications for the position as per relevant laws and regulations [2] Group 3 - The announcement includes a brief resume of Zhao Lijie, detailing his educational background and previous positions held in various companies [5] - As of the announcement date, Zhao Lijie indirectly holds 195,000 shares through Wuxi Weidafeng Investment Enterprise [6] - Zhao Lijie has no connections with shareholders holding more than 5% of the company's shares and has not faced any penalties from regulatory bodies [6][7]

2025 年 7 月 14 日 1 / 3 证券代码：301122 证券简称：采纳股份 公告编号：2025-064 采纳科技股份有限公司 关于补选非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）原任非独立董事侯鹏先生已于 2025 年 5 月 30 日辞任公司第三届董事会非独立董事职务，具体内容详见公司披 露于巨潮资讯网（http://www.cninfo.com.cn）的《关于董事辞职公告》，公告 编号：2025-046。 公司于 2025 年 7 月 14 日召开第三届董事会第十五次会议，审议通过了《关 于补选第三届董事会非独立董事的议案》，同意补选季春霞女士（简历附后）为 公司第三届董事会非独立董事候选人，任期自股东会审议通过之日起至第三届董 事会届满之日止。 特此公告。 采纳科技股份有限公司董事会 3 / 3 2 / 3 附件 季春霞女士简历 季春霞，女，1980 年生，中国国籍，无永久境外居留权，大专学历企业管理 专业；2007 年至 2017 年 2 月，任江阴采纳科技有限公司（公司前身）办 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-066 采纳科技股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事辞任的情况 采纳科技股份有限公司（以下简称"公司"）董事会近日收到公司非独立董 事赵丽杰先生的书面辞职报告。因公司内部工作调整，赵丽杰先生申请辞去公司 第三届董事会非独立董事职务，辞任后仍担任公司其他职务。赵丽杰先生的辞任 不会导致公司董事会人数低于法定最低人数，其书面辞职报告自送达公司董事会 之日起生效。 赵丽杰先生担任公司非独立董事的原定任期届满之日为 2026 年 7 月 13 日。 截至本公告披露日，赵丽杰先生未直接持有公司股份，亦不存在应当履行而未 履行的承诺事项。赵丽杰先生在原定任期内和任期届满后六个月内将继续遵守《深 圳证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持 股份》等法律法规、规范性文件对于离任董事股份管理的相关规定。 采纳科技股份有限公司董事会 2025 年 7 月 14 日 赵丽杰先生在任职公司非独立董事期间，恪尽职守、勤 ...